Clinical Research Directory
Browse clinical research sites, groups, and studies.
Long-term Safety and Tolerability of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria
Sponsor: Chengdu Suncadia Medicine Co., Ltd.
Summary
This is a multicenter, single-arm, open-label study. Patients with Paroxysmal Nocturnal Hemoglobinuria who had previously received and completed the HRS-5965 study well included. All eligible subjects received HRS-5965 tablets or capsules until the end of treatment in this study.
Official title: An Open Label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
132
Start Date
2024-02-06
Completion Date
2027-12
Last Updated
2025-12-24
Healthy Volunteers
No
Conditions
Interventions
HRS-5965 tablets
HRS-5965 tablets until the end of study treatment
HRS-5965 Capsules
HRS-5965 capsules.
Locations (2)
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
The Blood Disease Hospital of the Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China